Course 4 Updates: Generics and Biosimilars

We have recently updated Course 4 to include essential information on generics and biosimilars. As biosimilars begin to become available, it is important for the MS Nurse to ensure they are fully educated regarding the options, so that they are able to communicate effectively with the PwMS.

Studies in other therapy areas, where biosimilars are more established, have shown that the relationship between the healthcare provider and the patient is the foundation of how people will perceive and accept the new biosimilar treatments, limiting the risk of negative bias and the nocebo effect. 

The new section 3.4 Generics and biosimilars explains:

• what generics and biosimilars are,
• how biologics compare with biosimilars,
• their availability in Europe and,
• covers important nursing considerations.

The new section 3.4.1. spotlights Natalizumab-sztn and covers: 

• For which patient groups Natalizumab-sztn, a biosimilar parenteral DMT, developed to match the reference medicine (Tysabri®), is approved in Europe;
• Key efficacy data
• Important practical considerations, relevant for nurses, about the product, before starting the therapy, at start of the therapy, during therapy and when switching. 

The section includes a downloadable overview sheet (in English only).

These updates are designed to enhance your practice and improve patient outcomes. By understanding the latest in MS treatment options, you’ll be better prepared to support shared decision-making and build trust with your patients. Explore the updated course today and take the next step in delivering exceptional MS care!

Enroll in the course